Samsung Biologics Co (207940.KS) Stock Price
Samsung Biologics Co Price
Revenue has compounded at 59.3% per year over the past 12 years to 4.56 T KRW. Earnings per share have declined at 0.7% per year over the last 10 years. Samsung Biologics Co's net margin stands at 39.2%, up from 25.1% several years earlier. Analysts set a median price target of 2.24 M KRW, implying 54.4% above the current price. Of 31 analysts, 30 rate the stock a buy — an overall Buy consensus.
Samsung Biologics Co stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Samsung Biologics Co business model & stock analysis
Frequently asked questions about Samsung Biologics Co
Samsung Biologics Co Ltd is a leading biopharmaceutical contract development and manufacturing organization (CDMO). The company primarily focuses on providing development and manufacturing services for biopharmaceutical drugs and products. Leveraging state-of-the-art facilities and expertise in process development, Samsung Biologics offers end-to-end services, including cell line development, process development, clinical and commercial manufacturing, and analytical development. By offering a comprehensive range of services and utilizing cutting-edge technology, Samsung Biologics aims to support global companies in accelerating their drug development timelines and delivering high-quality biopharmaceutical products to patients worldwide.
Samsung Biologics Co Ltd is primarily active in the biopharmaceutical industry. With its state-of-the-art facilities and expertise in contract development and manufacturing organization (CDMO) services, Samsung Biologics focuses on the production and development of biologic drugs. From research and development to manufacturing and distribution, Samsung Biologics is committed to delivering high-quality healthcare solutions. Its comprehensive capabilities span across various therapeutic areas, including oncology, immunology, and other life-altering diseases. As a leading player in the biopharmaceutical sector, Samsung Biologics strives to drive innovation and contribute to the advancement of the global healthcare industry.
The main competitors of Samsung Biologics Co Ltd in the market are Lonza Group AG, Boehringer Ingelheim GmbH, and Catalent, Inc.
Samsung Biologics Co Ltd is a leading South Korean contract development and manufacturing organization (CDMO) that specializes in the production of biopharmaceuticals. Established in 2011, Samsung Biologics has quickly emerged as a prominent player in the biopharmaceutical industry, providing high-quality manufacturing and development services to global pharmaceutical companies. With state-of-the-art facilities and a team of experienced professionals, the company offers a comprehensive range of services, including cell line development, process development, and clinical and commercial manufacturing. Samsung Biologics has received numerous accolades for its expertise, reliability, and commitment to innovation, making it a trusted partner for biopharmaceutical companies worldwide.
Samsung Biologics Co Ltd has achieved several significant milestones. One notable achievement is its successful completion of the largest Bio CMO facility in the world, Plant 3, in 2018. This state-of-the-art facility showcases Samsung Biologics' commitment to innovation and expertise in biopharmaceutical manufacturing. Additionally, the company has attained numerous regulatory certifications and approvals, including the cGMP certification from the KFDA, FDA, EMA, and PMDA. Samsung Biologics has also formed strategic partnerships with leading pharmaceutical companies, demonstrating its capabilities and establishing itself as a trusted partner in the biopharmaceutical industry. These milestones highlight Samsung Biologics' continuous growth and recognition as a global leader in the field.
Samsung Biologics Co Ltd is primarily present in South Korea.
Samsung Biologics Co Ltd is a leading global manufacturer of biopharmaceuticals. With a strong focus on innovation and technology, the company represents values of excellence, integrity, and sustainability. As a pioneer in the biopharmaceutical industry, Samsung Biologics is committed to delivering high-quality and cost-effective products to meet the growing demand for advanced therapeutics worldwide. The company's corporate philosophy emphasizes collaboration, transparency, and customer-centricity, aiming to provide innovative solutions that improve the lives of patients. Samsung Biologics Co Ltd constantly strives for operational excellence, investing in state-of-the-art facilities and attracting top talent to drive advancements in the biopharmaceutical field.
Analysts currently set an average price target of 2.27 M KRW for the Samsung Biologics Co stock (median: 2.24 M KRW), implying +56.0 % versus the latest price. The consensus is based on 31 analyst ratings.
31 analysts currently rate the Samsung Biologics Co stock: 30 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Samsung Biologics Co to generate revenue of 5.56 T KRW and earnings per share of 27,499.81 KRW.
Converted at the current exchange rate, the Samsung Biologics Co share trades at 964.23 EUR (1.45 M KRW).
The Samsung Biologics Co share (207940.KS) is listed on 1 stock exchanges, including: KOSPI (Seoul) (207940.KS).
Samsung Biologics Co Ltd is a leading biopharmaceutical manufacturer focused on the development and production of biological drugs. The company is a subsidiary of the Samsung Group and is headquartered in Incheon, South Korea. Samsung Biologics offers a wide range of services in the field of biopharmacy, including development, manufacturing, and quality control. The business model of Samsung Biologics is based on providing customized solutions for the development and production of biological medicines. The company operates a state-of-the-art facility equipped with the latest technologies and meeting the highest industry standards. The company has three main areas: development, manufacturing, and quality assurance. Samsung Biologics offers a comprehensive range of services to support biological drug development, from preclinical development to clinical phases. The company works closely with its clients to create tailored development programs that meet their needs. The company has extensive experience in the development of monoclonal antibodies, recombinant proteins, peptides, antibody-drug conjugates, and other biologics. Samsung Biologics also offers a wide range of manufacturing services. There are three different production lines within the facility, including one for monoclonal antibodies, one for enzymes, and one for other biologics. These production lines are designed to provide flexible capacity and enable the production of different volumes. The company is also committed to continuously improving its quality assurance processes and meeting the highest industry standards to ensure the safety and efficacy of its products. Samsung Biologics has implemented a quality management system (QMS) that covers all aspects of biological drug development and manufacturing, and it strives to make continuous improvements in all areas of production. In addition to its core business areas, Samsung Biologics also offers other services such as analytical method development, stability studies, and non-clinical safety assessments. Overall, Samsung Biologics is a leading biopharmaceutical manufacturer that offers a comprehensive range of services in the field of biological drug development and manufacturing. Through its investments in cutting-edge technologies and commitment to the highest quality standards, the company is well positioned to meet the needs of its clients and have a positive impact on global health.
The expected revenue of Samsung Biologics Co is 5.56 T KRW. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Samsung Biologics Co is 1.82 T KRW. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Samsung Biologics Co is currently 52.84. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Samsung Biologics Co stock.
The price-to-sales ratio (P/S) of Samsung Biologics Co is currently 17.30. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Samsung Biologics Co stock.
The Eulerpool Quality Score for Samsung Biologics Co is 8/10.
The ISIN of Samsung Biologics Co is KR7207940008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Samsung Biologics Co is A2AUB1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Samsung Biologics Co is 207940.KS. The ticker symbol is used to trade Samsung Biologics Co shares on the stock exchange.
Samsung Biologics Co stock
Samsung Biologics Co Peer Group
Samsung Biologics Co Ticker
Samsung Biologics Co FIGI
All fundamentals and in-depth analysis of Samsung Biologics Co
Our stock analysis for Samsung Biologics Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Samsung Biologics Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.